Years in the un­mak­ing, CTI’s Pix­u­vri fails a piv­otal PhI­II com­bo study for lym­phoma — can it re­main on the mar­ket?

Seat­tle-based CTI Bio­Phar­ma’s $CTIC years-long saga de­vel­op­ing Pix­u­vri (pix­antrone) has run in­to an­oth­er stone wall. The com­pa­ny re­port­ed to­day that the drug, giv­en con­di­tion­al ap­proval in Eu­rope 6 years ago, failed a Phase III com­bi­na­tion study in B-cell non-Hodgkin lym­phoma.

Their drug com­bined with rit­ux­imab flunked a com­par­i­son with gem­c­itabine and rit­ux­imab in ex­tend­ing pro­gres­sion-free sur­vival. Their stock im­me­di­ate­ly plunged more than 20%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER